NEW YORK (GenomeWeb News) - Illumina shares were down more than 8 percent in mid-morning trade today following a report from a German newspaper in which a Roche official said that an acquisition of the San Diego-based company is "off the table."

At press time, Illumina shares were trading at $49.77, down from their Friday close of $54.76.

Roche Chairman Franz Humer said in an interview with Germany's SonntagsZeitung that the company has no plans to acquire Illumina, which he characterized as a "nice to have" but not a "must have."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.